Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma?
Publication date: Available online 9 April 2018 Source:The Lancet Haematology Author(s): Kevin A David, Athena Kritharis, Andrew M Evens (Source: The Lancet Haematology)
Source: The Lancet Haematology - April 10, 2018 Category: Hematology Source Type: research

Exposure to Coxiella burnetii and risk of non-Hodgkin lymphoma: a retrospective population-based analysis in the Netherlands
Publication date: Available online 9 April 2018 Source:The Lancet Haematology Author(s): Sonja E van Roeden, Fedor van Houwelingen, Chiel M J Donkers, Sander J Hogewoning, Marit M A de Lange, Wim van der Hoek, Linda M Kampschreur, Marc J M Bonten, Andy I M Hoepelman, Chantal P Bleeker-Rovers, Peter C Wever, Jan Jelrik Oosterheert Background An association between Coxiella burnetii and non-Hodgkin lymphoma has been suggested. After a large Q fever epidemic in the Netherlands (2007–10), we postulated that the incidence of non-Hodgkin lymphoma would be increased during and after the epidemic in areas with a high endemi...
Source: The Lancet Haematology - April 10, 2018 Category: Hematology Source Type: research

Defining clinically relevant measures of iron overload around haemopoietic stem cell transplantation
Publication date: Available online 5 April 2018 Source:The Lancet Haematology Author(s): Heather A Leitch (Source: The Lancet Haematology)
Source: The Lancet Haematology - April 6, 2018 Category: Hematology Source Type: research

Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial
Publication date: Available online 5 April 2018 Source:The Lancet Haematology Author(s): Martin Wermke, Julia Eckoldt, Katharina S Götze, Stefan A Klein, Gesine Bug, Liesbeth C de Wreede, Michael Kramer, Friedrich Stölzel, Malte von Bonin, Johannes Schetelig, Michael Laniado, Verena Plodeck, Wolf-Karsten Hofmann, Gerhard Ehninger, Martin Bornhäuser, Dominik Wolf, Igor Theurl, Uwe Platzbecker Background The effect of systemic iron overload on outcomes after allogeneic haemopoietic cell transplantation (HCT) has been a matter of substantial debate. We aimed to investigate the predictive value of both stored (...
Source: The Lancet Haematology - April 6, 2018 Category: Hematology Source Type: research

Bittersweet progress for haemophilia A
Publication date: April 2018 Source:The Lancet Haematology, Volume 5, Issue 4 Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 28, 2018 Category: Hematology Source Type: research

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
This study is registered with ClinicalTrials.gov, number NCT01403636, and has been completed. Findings Between Oct 19, 2011, and July 24, 2013, 167 patients were enrolled (42 with mantle cell lymphoma, 47 with follicular lymphoma, 42 with diffuse large B-cell lymphoma, and 36 with chronic lymphocytic leukaemia/small lymphocytic lymphoma. The median number of previous anticancer regimens was three (IQR 2–4) for patients with lymphoma and four (2–5) for patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. Of 164 patients evaluable for efficacy, 30 (18·3%) achieved an overall response (pa...
Source: The Lancet Haematology - March 15, 2018 Category: Hematology Source Type: research

Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor
Publication date: Available online 14 March 2018 Source:The Lancet Haematology Author(s): Wataru Munakata, Kensei Tobinai (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 15, 2018 Category: Hematology Source Type: research

Conditioning intensity in HCT for AML: the jury is still out
Publication date: Available online 14 March 2018 Source:The Lancet Haematology Author(s): Charles Craddock (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 15, 2018 Category: Hematology Source Type: research

Grb2 inhibition: a new potential targeted therapy for myeloid malignancies?
Publication date: Available online 14 March 2018 Source:The Lancet Haematology Author(s): Xavier Thomas, Etienne Paubelle (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 15, 2018 Category: Hematology Source Type: research

Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial
Publication date: Available online 14 March 2018 Source:The Lancet Haematology Author(s): Frederick Fasslrinner, Johannes Schetelig, Andreas Burchert, Michael Kramer, Rudolf Trenschel, Ute Hegenbart, Michael Stadler, Kerstin Schäfer-Eckart, Michael Bätzel, Hans Eich, Martin Stuschke, Rita Engenhart-Cabillic, Mechthild Krause, Peter Dreger, Andreas Neubauer, Gerhard Ehninger, Dietrich Beelen, Wolfgang E Berdel, Timo Siepmann, Matthias Stelljes, Martin Bornhäuser Background The impact of the intensity of conditioning before allogeneic haemopoietic cell transplantation (HCT) has been studied in a randomised ph...
Source: The Lancet Haematology - March 15, 2018 Category: Hematology Source Type: research

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial
We report the first phase 1 findings of BP1001. Methods In this single-centre, open-label, dose-escalation phase 1/1b trial, we enrolled participants (aged ≥18 years) with refractory or relapsed acute myeloid leukaemia, Philadelphia-chromosome-positive chronic myeloid leukaemia (in chronic, accelerated, or blast phase), acute lymphoblastic leukaemia, or myelodysplastic syndrome, at MD Anderson Cancer Center (Houston, TX, USA). We used a 3 + 3 dose escalation strategy, with at least three patients enrolled at each dose level. We administered BP1001 intravenously, twice weekly, for 28 days, with a starting dose of 5 m...
Source: The Lancet Haematology - March 15, 2018 Category: Hematology Source Type: research

Ready-to-use food supplement, with or without arginine and citrulline, with daily chloroquine in Tanzanian children with sickle-cell disease: a double-blind, random order crossover trial
Publication date: Available online 13 March 2018 Source:The Lancet Haematology Author(s): Sharon E Cox, Elizabeth A Ellins, Alphonce I Marealle, Charles R Newton, Deogratias Soka, Philip Sasi, Gian Luca Di Tanna, William Johnson, Julie Makani, Andrew M Prentice, Julian P Halcox, Fenella J Kirkham Background Sickle-cell disease increases the risk of malnutrition. Low arginine and nitric oxide bioavailability are implicated in morbidity related to sickle-cell disease. Simple interventions are required, especially in low-income settings. We aimed to test the hypotheses that: (1) supplementary arginine, citrulline, and daily ...
Source: The Lancet Haematology - March 14, 2018 Category: Hematology Source Type: research

Sickle-cell anaemia needs more food?
Publication date: Available online 13 March 2018 Source:The Lancet Haematology Author(s): Hyacinth I Hyacinth (Source: The Lancet Haematology)
Source: The Lancet Haematology - March 14, 2018 Category: Hematology Source Type: research

CAR T-cell design: a long road ahead
Publication date: March 2018 Source:The Lancet Haematology, Volume 5, Issue 3 Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 28, 2018 Category: Hematology Source Type: research

Revisiting WHO haemoglobin thresholds to define anaemia in clinical medicine and public health
Publication date: February 2018 Source:The Lancet Haematology, Volume 5, Issue 2 Author(s): Sant-Rayn Pasricha, Katherine Colman, Elizabeth Centeno-Tablante, Maria-Nieves Garcia-Casal, Juan-Pablo Peña-Rosas (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 2, 2018 Category: Hematology Source Type: research

Rituximab maintenance is efficacious, but is it useful?
Publication date: February 2018 Source:The Lancet Haematology, Volume 5, Issue 2 Author(s): Susan O'Brien (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 2, 2018 Category: Hematology Source Type: research

Challenges and new horizons for sickle cell disease
Publication date: February 2018 Source:The Lancet Haematology, Volume 5, Issue 2 Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - February 2, 2018 Category: Hematology Source Type: research

Can we improve on ibrutinib in mantle cell lymphoma?
Publication date: Available online 29 January 2018 Source:The Lancet Haematology Author(s): Simon Rule (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 30, 2018 Category: Hematology Source Type: research

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Publication date: Available online 29 January 2018 Source:The Lancet Haematology Author(s): Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Helle Toldbod, Lone Bredo Pedersen, Carsten Utoft Niemann, Christina Dahl, Hanne Kuitunen, Christian H Geisler, Kirsten Grønbæk, Arne Kolstad Background Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previo...
Source: The Lancet Haematology - January 30, 2018 Category: Hematology Source Type: research

Consolidation and maintenance in follicular lymphoma: radioimmunotherapy revisited?
Publication date: Available online 26 January 2018 Source:The Lancet Haematology Author(s): Leo I Gordon (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 27, 2018 Category: Hematology Source Type: research

R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study
Publication date: Available online 26 January 2018 Source:The Lancet Haematology Author(s): Paul M Barr, Hongli Li, W Richard Burack, Michael LeBlanc, Sonali M Smith, Ajay K Gopal, Justin D Floyd, Daniel O Persky, Oliver W Press, Richard I Fisher, Jonathan W Friedberg Background Despite an abundance of therapeutic options, advanced-stage follicular lymphoma remains incurable. Furthermore, the ideal sequence and absolute benefit of post-induction therapy is unclear. We designed SWOG S0801 to assess the efficacy and safety of consolidative radioimmunotherapy and sequential maintenance rituximab following chemoimmunotherapy....
Source: The Lancet Haematology - January 27, 2018 Category: Hematology Source Type: research

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial
This study is a 5-year follow-up of a phase 2, multicentre, double-blind trial of romiplostim treatment in patients with lower-risk myelodysplastic syndromes. Eligible patients were recruited at 109 centres in North America, Europe, Russia, and Australia, were aged 18–90 years, and had platelets of 20 × 109 per L or less with or without a history of bleeding or 50 × 109 platelets per L or less with a history of bleeding. Patients were randomly assigned by interactive voice response system with stratification by baseline platelet count (≥20 × 109 per L or <20 × 109 per...
Source: The Lancet Haematology - January 27, 2018 Category: Hematology Source Type: research

Good news for patients with myelodysplastic syndromes and thrombocytopenia
Publication date: Available online 26 January 2018 Source:The Lancet Haematology Author(s): Moshe Mittelman (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 27, 2018 Category: Hematology Source Type: research

Of blood and bone: the sotatercept adventure
Publication date: Available online 10 January 2018 Source:The Lancet Haematology Author(s): Valeria Santini (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 11, 2018 Category: Hematology Source Type: research

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Publication date: Available online 10 January 2018 Source:The Lancet Haematology Author(s): Rami Komrokji, Guillermo Garcia-Manero, Lionel Ades, Thomas Prebet, David P Steensma, Joseph G Jurcic, Mikkael A Sekeres, Jesus Berdeja, Michael R Savona, Odile Beyne-Rauzy, Aspasia Stamatoullas, Amy E DeZern, Jacques Delaunay, Gautam Borthakur, Robert Rifkin, Thomas E Boyd, Abderrhamane Laadem, Bond Vo, Jennie Zhang, Marie Puccio-Pick, Kenneth M Attie, Pierre Fenaux, Alan F List Background Myelodysplastic syndromes are characterised by ineffective erythropoiesis leading to anaemia. Sotatercept (ACE-011) is a novel activin receptor...
Source: The Lancet Haematology - January 11, 2018 Category: Hematology Source Type: research

Epidemiological patterns of leukaemia in 184 countries: a population-based study
Publication date: January 2018 Source:The Lancet Haematology, Volume 5, Issue 1 Author(s): Adalberto Miranda-Filho, Marion Piñeros, Jacques Ferlay, Isabelle Soerjomataram, Alain Monnereau, Freddie Bray Background Leukaemia is a heterogeneous group of haemopoietic cancers that comprises a number of diverse and biologically distinct subgroups. We examine the leukaemia burden worldwide and highlight the distinct incidence patterns in order to elucidate explanatory factors that may support preventive measures and health resource planning. We aimed to estimate the global burden of leukaemia incidence according to the fo...
Source: The Lancet Haematology - December 29, 2017 Category: Hematology Source Type: research

59th American Society of Hematology Annual Meeting
Publication date: January 2018 Source:The Lancet Haematology, Volume 5, Issue 1 Author(s): Farhat Yaqub (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 29, 2017 Category: Hematology Source Type: research

Intravenous iron: out of sight, out of mind
Publication date: January 2018 Source:The Lancet Haematology, Volume 5, Issue 1 Author(s): Michael Auerbach, Manuel Muñoz, Iain C Macdougall (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 29, 2017 Category: Hematology Source Type: research

Stockings to prevent post-thrombotic syndrome —where are we now?
Publication date: January 2018 Source:The Lancet Haematology, Volume 5, Issue 1 Author(s): David Keeling (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 29, 2017 Category: Hematology Source Type: research

Leukaemia prevalence worldwide: raising aetiology questions
Publication date: January 2018 Source:The Lancet Haematology, Volume 5, Issue 1 Author(s): Pedro Dantas Oliveira (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 29, 2017 Category: Hematology Source Type: research

The global burden of haematological diseases
Publication date: January 2018 Source:The Lancet Haematology, Volume 5, Issue 1 Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 29, 2017 Category: Hematology Source Type: research

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Publication date: Available online 20 December 2017 Source:The Lancet Haematology Author(s): Claire N Harrison, Alessandro M Vannucchi, Uwe Platzbecker, Francisco Cervantes, Vikas Gupta, David Lavie, Francesco Passamonti, Elliott F Winton, Hua Dong, Jun Kawashima, Julia D Maltzman, Jean-Jacques Kiladjian, Srdan Verstovsek Background The Janus kinase (JAK) inhibitor ruxolitinib is the only approved therapy for patients with symptomatic myelofibrosis. After ruxolitinib failure, however, there are few therapeutic options. We assessed the efficacy and safety of momelotinib, a JAK 1 and JAK 2 inhibitor, versus best available t...
Source: The Lancet Haematology - December 21, 2017 Category: Hematology Source Type: research

Don't judge a JAK2 inhibitor by spleen response alone
Publication date: Available online 20 December 2017 Source:The Lancet Haematology Author(s): John Mascarenhas, Ronald Hoffman (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 21, 2017 Category: Hematology Source Type: research

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study
Publication date: Available online 20 December 2017 Source:The Lancet Haematology Author(s): Caroline Dartigeas, Eric Van Den Neste, Julie Léger, Hervé Maisonneuve, Christian Berthou, Marie-Sarah Dilhuydy, Sophie De Guibert, Stéphane Leprêtre, Marie C Béné, Florence Nguyen-Khac, Rémi Letestu, Florence Cymbalista, Philippe Rodon, Thérèse Aurran-Schleinitz, Jean-Pierre Vilque, Olivier Tournilhac, Béatrice Mahé, Kamel Laribi, Anne-Sophie Michallet, Alain Delmer, Pierre Feugier, Vincent Lévy, Roselyne Delépine, Philippe Colombat, V&eacut...
Source: The Lancet Haematology - December 21, 2017 Category: Hematology Source Type: research

Imaging bone-marrow activity with 18F-fluorothymidine PET
Publication date: Available online 14 December 2017 Source:The Lancet Haematology Author(s): Anthony F Shields (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 14, 2017 Category: Hematology Source Type: research

Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study
This study is registered with ClinicalTrials.gov, number NCT01338987. Findings Between April 1, 2014, and Dec 31, 2015, 23 patients were enrolled and assessable for toxic effects after completing accrual. 18F-FLT was not associated with any adverse events or delayed engraftment. 18F-FLT imaging objectively identified subclinical bone-marrow recovery within 5 days of HSC infusion, which was up to 20 days before engraftment became clinically evident. Quantitatively, 18F-FLT intensity differed significantly between myeloablative infusion before HSCT and subclinical HSC recovery (p=0·00031). 18F-FLT biodistribution over...
Source: The Lancet Haematology - December 14, 2017 Category: Hematology Source Type: research

Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML
Publication date: Available online 11 December 2017 Source:The Lancet Haematology Author(s): Aditi Shastri, Amit K Verma (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 12, 2017 Category: Hematology Source Type: research

Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial
In this study (ASPIRE), we aimed to assess eltrombopag, an oral thrombopoietin receptor agonist, for thrombocytopenia (grade 4) treatment in adult patients with advanced MDS or AML. Methods ASPIRE consisted of an open-label, double-blind phase for 8 weeks and a randomised, double-blind phase (parts 1 and 2, reported here) for 12 weeks, and an open-label extension (part 3). Eligible patients were men and women aged 18 years or older, with intermediate-2 or high-risk MDS or AML, with bone marrow blasts of 50% or less, and had either grade 4 thrombocytopenia due to bone marrow insufficiency (platelet counts <25 &time...
Source: The Lancet Haematology - December 12, 2017 Category: Hematology Source Type: research

Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial
This study was a multicentre, participant-blinded, randomised controlled trial done at three centres in Australia. We enrolled people who were homozygous for HFE p.Cys282Tyr, aged between 18 and 70 years, with moderately elevated serum ferritin, defined as 300–1000 μg/L, and raised transferrin saturation. Participants were randomly assigned, via a computer-generated random number, to undergo either iron reduction by erythrocytapheresis (treatment group) or sham treatment by plasmapheresis (control group). Randomisation was stratified by baseline serum ferritin (<600 μg/L or ≥600 μg/L), sex, and stu...
Source: The Lancet Haematology - December 11, 2017 Category: Hematology Source Type: research

Should we treat individuals homozygous for HFE p.Cys282Tyr with ferritin 300 –1000 μg/L?
Publication date: December 2017 Source:The Lancet Haematology, Volume 4, Issue 12 Author(s): James C Barton (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 11, 2017 Category: Hematology Source Type: research

Serum protein markers of clonal heterogeneity in myeloma
Publication date: December 2017 Source:The Lancet Haematology, Volume 4, Issue 12 Author(s): Ola Landgren (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 11, 2017 Category: Hematology Source Type: research

A step towards precision medicine in management of fever and neutropenia in haematology
Publication date: December 2017 Source:The Lancet Haematology, Volume 4, Issue 12 Author(s): Claudio Viscoli (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 11, 2017 Category: Hematology Source Type: research

Orphan drug approval for Erdheim-Chester disease
Publication date: December 2017 Source:The Lancet Haematology, Volume 4, Issue 12 Author(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 11, 2017 Category: Hematology Source Type: research

Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial
This study has been completed and is registered with ClinicalTrials.gov, number NCT01429714. Findings Between March 22, 2011, and July 1, 2015, we enrolled 865 patients and randomly assigned 437 to individualised duration compression stockings and 428 to standard duration. 283 (66%) of 432 patients in the intervention group were advised before 24 months to stop wearing elastic compression stockings (236 [55%] of 432 patients after 6 months, and 47 [11%] of 432 at 12 months). Post-thrombotic syndrome occurred in 125 (29%) of 432 patients receiving individualised duration of therapy and in 118 (28%) of 424 receiving standard...
Source: The Lancet Haematology - December 11, 2017 Category: Hematology Source Type: research

Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study
Publication date: November 2017 Source:The Lancet Haematology, Volume 4, Issue 11 Author(s): Elizabeth S Allen, Kshitij Srivastava, Matthew M Hsieh, Courtney D Fitzhugh, Harvey G Klein, John F Tisdale, Willy A Flegel Background Haemopoietic progenitor cell (HPC) transplantation can cure sickle cell disease. Non-myeloablative conditioning typically results in donor-derived erythrocytes and stable mixed chimerism of recipient-derived and donor-derived leucocytes. Exposure to donor antigens from the HPC graft and new red cell antibodies induced by transfusion can lead to immunohaematological complications. We assessed the in...
Source: The Lancet Haematology - November 19, 2017 Category: Hematology Source Type: research

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
This study is registered with ClinicalTrials.gov, number NCT01011920. Findings Between Feb 19, 2010, and Aug 27, 2014, 227 patients were recruited from 53 centres in five countries. 219 of 227 enrolled patients were assessable. Of the 122 patients eligible for the second randomisation, 118 patients were randomly assigned to WBRT or ASCT (59 patients per group) and constitute the study population. WBRT and ASCT were both effective, and achieved the predetermined efficacy threshold of at least 40 progression-free survivors at 2 years among the first 52 patients in both groups D and E. There were no significant differences in...
Source: The Lancet Haematology - November 19, 2017 Category: Hematology Source Type: research

Authors' reply to comment What should be the endpoints of a symptomatic drug and its control?
Publication date: November 2017 Source:The Lancet Haematology, Volume 4, Issue 11 Author(s): Ruben Mesa, Claire Harrison (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 19, 2017 Category: Hematology Source Type: research

Authors' reply to comment Blood transfusion strategies in elderly patients
Publication date: November 2017 Source:The Lancet Haematology, Volume 4, Issue 11 Author(s): Geoff I Simon, Alison Craswell, Ogilvie Thom, Yoke Lin Fung (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 19, 2017 Category: Hematology Source Type: research

Red blood cell alloimmunisation in patients with sickle cell disease
Publication date: November 2017 Source:The Lancet Haematology, Volume 4, Issue 11 Author(s): Fernanda Volt (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 19, 2017 Category: Hematology Source Type: research

An alternative to radiotherapy in consolidation of brain lymphoma
Publication date: November 2017 Source:The Lancet Haematology, Volume 4, Issue 11 Author(s): David Schiff (Source: The Lancet Haematology)
Source: The Lancet Haematology - November 19, 2017 Category: Hematology Source Type: research